AMENDMENTS TO THE CLAIMS

Please amend the claims as follows:

Claim 1 (Currently amended). A compound of formula (I):



(I)

or an enantiomer, diastereomer, or a pharmaceutically acceptable salt~~, prodrug, or solvate~~ thereof, wherein

Z is selected from O, S, N, OH, or Cl, with the provisos that when Z is O or S, R^{41} is absent and when Z is OH or Cl, both R^{41} and R^{42} are absent and when Z is N, then R^{41} is H;

X and Y are independently selected from O, OCO, S, SO, SO_2, CO, CO_2, NR^{10}, $NR^{11}CO$, $NR^{12}CONR^{13}$, $NR^{14}CO_2$, $NR^{15}SO_2$, $NR^{16}SO_2NR^{17}$, SO_2NR^{18}, $CONR^{19}$, halogen, nitro, cyano, or X or Y are absent;

R1 is hydrogen, CH_3, OH, OCH_3, SH, SCH_3, $OCOR^{21}$, SOR^{22}, SO_2R^{23}, $SO_2NR^{24}R^{25}$, CO_2R^{26}, $CONR^{27}R^{28}$, NH_2, $NR^{29}SO_2NR^{30}R^{31}$, $NR^{32}SO_2R^{33}$, $NR^{34}COR^{35}$, $NR^{36}CO_2R^{37}$, $NR^{38}CONR^{39}R^{40}$, halogen, nitro, or cyano;

R^2 is ~~and R^3 are~~ independently hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, heterocyclo, substituted heterocyclo, aralkyl, substituted aralkyl, heterocycloalkyl or substituted heterocycloalkyl, or when X is halo, nitro or cyano, R^2 is absent ~~or when Y is halo, nitro or cyano R^3 is absent~~;

R^3 is independently hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, heterocyclo, substituted heterocyclo, aralkyl, substituted aralkyl, heterocycloalkyl or substituted heterocycloalkyl, or when Y is halo, nitro or cyano, R^3 is absent, with the proviso that R^3 is not methyl;

R^6 is hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, heterocyclo, substituted heterocyclo, NR^7R^8, OR^9 or halogen;

R^7, R^8, R^9, R^{10}, R^{11}, R^{12}, R^{13}, R^{14}, R^{15}, R^{16}, R^{17}, R^{18}, R^{19}, R^{21}, R^{24}, R^{25}, R^{26}, R^{27}, R^{28}, R^{29}, R^{30}, R^{31}, R^{32}, R^{34}, R^{35}, R^{36}, R^{38}, R^{39} and R^{40} are independently selected from the group consisting of hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, heterocyclo, or substituted heterocyclo;

R^{22}, R^{23}, R^{33} and R^{37} are independently selected from the group consisting of alkyl, substituted alkyl, aryl, substituted aryl, heterocyclo, or substituted heterocyclo; and

R^{42} is 

wherein

each R^{43} is independently selected from fluorine or methyl;

n is 0, 1 or 2; and

R^{44} is methyl, ethyl or cyclopropylmethyl;

with the further provisos that:

a. R^2 may not be hydrogen if X is SO, SO_2, $NR^{13}CO_2$, or $NR^{14}SO_2$, and

b. R^3 may not be hydrogen if Y is SO, SO_2, $NR^{13}CO_2$, or $NR^{14}SO_2$.

Claim 2 (Currently amended). The compound of formula (I) according to Claim 1, selected from the group consisting of:

5-(1-Methylethyl)pyrrolo[2,1-f][1,2,4]triazin-4(3H)-one-6-carboxylic acid ethyl ester,

4-Chloro-[2,1-f][1,2,4]triazin-5-(1-Methylethyl)pyrrolo-6-carboxylic acid ethyl ester,

4-Chloro-5-(1-methylethyl)-6-(5-methyl-2-oxazolyl)pyrrolo[2,1-f][1,2,4]triazin,

4-[[3-[(Methoxyamino)carbonyl]phenyl]amino]-5-(1-methylethyl)pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid ethyl ester,

4-[[2-Fluoro-5-[(methoxyamino)carbonyl]phenyl]amino]-5-(1-methylethyl)pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid ethyl ester,

4-[[2-Fluoro-5-[(methoxyamino)carbonyl]-4-methylphenyl]amino]-5-(1-methylethyl)pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid ethyl ester,

4-[[3-[(Methoxyamino)carbonyl]-4-methylphenyl]amino]-5-(1-methylethyl)pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid ethyl ester,

4-[[4-Fluoro-3-[(methoxyamino)carbonyl]phenyl]amino]-5-(1-methylethyl)pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid ethyl ester,

4-[[2,4-Difluoro-5-[(methoxyamino)carbonyl]phenyl]amino]-5-(1-methylethyl)pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid ethyl ester,

4-[3-[(Methoxyamino)carbonyl]phenoxy]-5-(1-methylethyl)pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid, ethyl ester,

4-[2-Fluoro-3-[(methoxyamino)carbonyl]phenoxy]-5-(1-methylethyl)pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid, ethyl ester,

4-[[2-Fluoro-5-[(methoxyamino)carbonyl]phenyl]amino]-5-(1-methylethyl)pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid,

N-Ethyl-4-[[2-fluoro-5-[(methoxyamino)carbonyl]phenyl]amino]-5-(1-methylethyl)pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide,

N-[2-(Dimethylamino)ethyl]-4-[[2-fluoro-5-[(methoxyamino)carbonyl] phenyl]amino]-5-(1-methylethyl)pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide,

4-[[2-Fluoro-5-[(methoxyamino)carbonyl]phenyl]amino]-N-(2-hydroxyethyl)-5-(1-methylethyl)pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide,

4-[[3-[(Methoxyamino)carbonyl]-4-methylphenyl]amino]-N-methyl-5-(1-methylethyl)pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide,

4-[[3-[(Methoxyamino)carbonyl]-4-methylphenyl]amino]-5-(1-methylethyl)-N-[2-(1-pyrrolidinyl)ethyl]pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide,

[4-[[3-[(Methoxyamino)carbonyl]-4-methylphenyl]amino]-5-(1-methylethyl)pyrrolo[2,1-f][1,2,4]triazin-6-yl]carbamic acid 2-(1-methyl-2-pyrrolidinyl)ethyl ester,

4-[[2,4-Difluoro-5-[(methoxyamino)carbonyl]phenyl]amino]-5-(1-methylethyl)pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid,

[4-[[2,4-Difluoro-5-[(methoxyamino)carbonyl]phenyl]amino]-5-(1-methylethyl)pyrrolo[2,1-f][1,2,4]triazin-6-yl]carbamic acid 3-(methylsulfonyl)propyl ester,

[4-[[2,4-Difluoro-5-[(methoxyamino)carbonyl]phenyl]amino]-5-(1-methylethyl)pyrrolo[2,1-f][1,2,4]triazin-6-yl]carbamic acid ethyl ester,

[4-[[2,4-Difluoro-5-[(methoxyamino)carbonyl]phenyl]amino]-5-(1-methylethyl)pyrrolo[2,1-f][1,2,4]triazin-6-yl]carbamic acid 3-(1-piperidinyl)propyl ester,

5-[[6-[5-(Difluoromethyl)-1,3,4-oxadiazol-2-yl]-5-(1-methylethyl)pyrrolo[2,1-f][1,2,4]triazin-4-yl]amino]-2,4-difluoro-N-methoxybenzamide,

5-[[6-Ethoxy-5-(1-methylethyl)pyrrolo[2,1-f][1,2,4]triazin-4-yl]amino]-4-fluoro-N-methoxy-2-methylbenzamide,

5-[[6-Acetyl-5-(1-methylethyl)pyrrolo[2,1-f][1,2,4]triazin-4-yl]amino]-N-methoxy-2-methylbenzamide,

2,4-Difluoro-N-methoxy-5-[[5-(1-methylethyl)-6-(2-methyl-1H-1,2,4-triazol-3-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl]amino]benzamide,

2,4-Difluoro-N-methoxy-5-[[5-(1-methylethyl)-6-(1-methyl-1H-1,2,4-triazol-3-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl]amino]benzamide,

2,4-Difluoro-N-methoxy-5-[[5-(1-methylethyl)-6-[5-[(methylsulfonyl)methyl]-1,3,4-oxadiazol-2-yl]pyrrolo[2,1-f][1,2,4]triazin-4-yl]amino]benzamide,

5-[[6-[5-[Difluoro(methylsulfonyl)methyl]-1,3,4-oxadiazol-2-yl]-5-(1-methylethyl)pyrrolo[2,1-f][1,2,4]triazin-4-yl]amino]-2,4-difluoro-N-methoxybenzamide,

5-[[6-[5-(Dimethylamino)-1,3,4-oxadiazol-2-yl]-5-(1-methylethyl)pyrrolo[2,1-f][1,2,4]triazin-4-yl]amino]-2,4-difluoro-N-methoxybenzamide,

[4-[[2,4-Difluoro-5-[(methoxyamino)carbonyl]phenyl]amino]-5-(1-methylethyl)pyrrolo[2,1-f][1,2,4]triazin-6-yl]carbamic acid 2-(1-methyl-1H-1,2,4-triazol-5-yl)ethyl ester,

[4-[[2,4-Difluoro-5-[(methoxyamino)carbonyl]phenyl]amino]-5-(1-methylethyl)pyrrolo[2,1-f][1,2,4]triazin-6-yl]carbamic acid, (1-methyl-4-piperidinyl)methyl,

[4-[[2,4-Difluoro-5-[(methoxyamino)carbonyl]phenyl]amino]-5-(1-methylethyl)pyrrolo[2,1-f][1,2,4]triazin-6-yl]carbamic acid, 3-(1H-1,2,3-triazol-1-yl)propyl ester,

[4-[[2,4-Difluoro-5-[(methoxyamino)carbonyl]phenyl]amino]-5-(1-methylethyl)pyrrolo[2,1-f][1,2,4]triazin-6-yl]carbamic acid, 2-(1H-1,2,3-triazol-1-yl)ethyl ester,

[4-[[2,4-Difluoro-5-[(methoxyamino)carbonyl]phenyl]amino]-5-(1-methylethyl)pyrrolo[2,1-f][1,2,4]triazin-6-yl]carbamic acid, 3-(6-methyl-2-pyridinyl) propyl ester

[4-[[2,4-Difluoro-5-[(methoxyamino)carbonyl]phenyl]amino]-5-(1-methylethyl)pyrrolo[2,1-f][1,2,4]triazin-6-yl]carbamic acid 2-(methylsulfonyl)ethyl ester,

[4-[[2,4-Difluoro-5-[(methoxyamino)carbonyl]phenyl]amino]-5-(1-methylethyl)pyrrolo[2,1-f][1,2,4]triazin-6-yl]carbamic acid (2-butyl-1H-imidazol-4-yl)methyl ester,

[4-[[2,4-Difluoro-5-[(methoxyamino)carbonyl]phenyl]amino]-5-(1-methylethyl)pyrrolo[2,1-f][1,2,4]triazin-6-yl]carbamic acid 2-(4-pyridinyl)ethyl ester,

[4-[[2,4-Difluoro-5-[(methoxyamino)carbonyl]phenyl]amino]-5-(1-methylethyl)pyrrolo[2,1-f][1,2,4]triazin-6-yl]carbamic acid 2-(dimethoxyphosphinyl)ethyl ester,

[4-[[2,4-Difluoro-5-[(methoxyamino)carbonyl]phenyl]amino]-5-(1-methylethyl)pyrrolo[2,1-f][1,2,4]triazin-6-yl]carbamic acid (6-methyl-2-pyridinyl)methyl ester,

[4-[[2,4-Difluoro-5-[(methoxyamino)carbonyl]phenyl]amino]-5-(1-methylethyl)pyrrolo[2,1-f][1,2,4]triazin-6-yl]carbamic acid [(2S)-1-methyl-2-pyrrolidinyl]methyl ester,

[4-[[2,4-Difluoro-5-[(methoxyamino)carbonyl]phenyl]amino]-5-(1-methylethyl)pyrrolo[2,1-f][1,2,4]triazin-6-yl]carbamic acid (1-methyl-2-piperidinyl)methyl ester,

[4-[[2,4-Difluoro-5-[(methoxyamino)carbonyl]phenyl]amino]-5-(1-methylethyl)pyrrolo[2,1-f][1,2,4]triazin-6-yl]carbamic acid 1-methyl-4-piperidinyl ester,

[4-[[2,4-Difluoro-5-[(methoxyamino)carbonyl]phenyl]amino]-5-(1-methylethyl)pyrrolo[2,1-f][1,2,4]triazin-6-yl]carbamic acid 4-pyridinylmethyl ester,

[4-[[2,4-Difluoro-5-[(methoxyamino)carbonyl]phenyl]amino]-5-(1-methylethyl)pyrrolo[2,1-f][1,2,4]triazin-6-yl]carbamic acid 3-pyridinylmethyl ester,

[4-[[2,4-Difluoro-5-[(methoxyamino)carbonyl]phenyl]amino]-5-(1-methylethyl)pyrrolo[2,1-f][1,2,4]triazin-6-yl]carbamic acid 2-(2-pyridinyl)ethyl ester,

[4-[[2,4-Difluoro-5-[(methoxyamino)carbonyl]phenyl]amino]-5-(1-methylethyl)pyrrolo[2,1-f][1,2,4]triazin-6-yl]carbamic acid 2-pyridinylmethyl ester,

[4-[[2,4-Difluoro-5-[(methoxyamino)carbonyl]phenyl]amino]-5-(1-methylethyl)pyrrolo[2,1-f][1,2,4]triazin-6-yl]carbamic acid 2-(4-morpholinyl)ethyl ester,

[4-[[2,4-Difluoro-5-[(methoxyamino)carbonyl]phenyl]amino]-5-(1-methylethyl)pyrrolo[2,1-f][1,2,4]triazin-6-yl]carbamic acid 2-(1-methyl-2-pyrrolidnyl)ethyl ester,

[4-[[2,4-Difluoro-5-[(methoxyamino)carbonyl]phenyl]amino]-5-(1-methylethyl)pyrrolo[2,1-f][1,2,4]triazin-6-yl]carbamic acid 1-methyl-3-pyrrolidnyl ester,

[4-[[2,4-Difluoro-5-[(methoxyamino)carbonyl]phenyl]amino]-5-(1-methylethyl)pyrrolo[2,1-f][1,2,4]triazin-6-yl]carbamic acid 2-ethoxyethyl ester,

[4-[[2,4-Difluoro-5-[(methoxyamino)carbonyl]phenyl]amino]-5-(1-methylethyl)pyrrolo[2,1-f][1,2,4]triazin-6-yl]carbamic acid [5-[(dimethylamino)methyl]-2-furanyl]methyl ester,

[4-[[2,4-Difluoro-5-[(methoxyamino)carbonyl]phenyl]amino]-5-(1-methylethyl)pyrrolo[2,1-f][1,2,4]triazin-6-yl]carbamic acid 2-(1-piperidinyl)ethyl ester,

[4-[[2,4-Difluoro-5-[(methoxyamino)carbonyl]phenyl]amino]-5-(1-methylethyl)pyrrolo[2,1-f][1,2,4]triazin-6-yl]carbamic acid 3-hydroxybutyl ester,

4-Fluoro-N-methoxy-3-[[5-(1-methylethyl)-6-(5-methyl-2-oxazolyl)pyrrolo[2,1-f][1,2,4]triazin-4-yl]amino]benzamide,

2,4-Difluoro-N-methoxy-5-[[5-(1-methylethyl)-6-(5-methyl-2-oxazolyl)pyrrolo[2,1-f][1,2,4]triazin-4-yl]amino]benzamide,

2-Fluoro-N-methoxy-5-[[5-(1-methylethyl)-6-(5-methyl-2-oxazolyl)pyrrolo[2,1-f][1,2,4]triazin-4-yl]amino]benzamide,

N-Methoxy-2-methyl-5-[[5-(1-methylethyl)-6-(5-methyl-2-oxazolyl)pyrrolo[2,1-f][1,2,4]triazin-4-yl]amino]benzamide,

4-Fluoro-N-methoxy-2-methyl-5-[[5-(1-methylethyl)-6-(5-methyl-2-oxazolyl)pyrrolo[2,1-f][1,2,4]triazin-4-yl]amino]benzamide,

2-Chloro-N-methoxy-5-[[5-(1-methylethyl)-6-(5-methyl-2-oxazolyl)pyrrolo[2,1-f][1,2,4]triazin-4-yl]amino]benzamide,

2,4-Difluoro-N-methoxy-5-[[5-(1-methylethyl)-6-(5-methyl-1,2,4-oxadiazol-3-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl]amino]benzamide,

or a ~~and~~ pharmaceutically acceptable salt ~~salts and prodrugs~~ thereof.

Claim 3 (Original). A compound selected from the group consisting of

[4-[[2,4-Difluoro-5-[(methoxyamino)carbonyl]phenyl]amino]-5-(1-methylethyl)pyrrolo[2,1-f][1,2,4]triazin-6-yl]carbamic acid 3-(methylsulfonyl)propyl ester,

[4-[[2,4-Difluoro-5-[(methoxyamino)carbonyl]phenyl]amino]-5-(1-methylethyl)pyrrolo[2,1-f][1,2,4]triazin-6-yl]carbamic acid 3-(1-piperidinyl)propyl ester,

5-[[6-[5-(Difluoromethyl)-1,3,4-oxadiazol-2-yl]-5-(1-methylethyl)pyrrolo[2,1-f][1,2,4]triazin-4-yl]amino]-2,4-difluoro-N-methoxybenzamide,

2,4-Difluoro-N-methoxy-5-[[5-(1-methylethyl)-6-(2-methyl-1H-1,2,4-triazol-3-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl]amino]benzamide,

2,4-Difluoro-N-methoxy-5-[[5-(1-methylethyl)-6-[5-[(methylsulfonyl)methyl]-1,3,4-oxadiazol-2-yl]pyrrolo[2,1-f][1,2,4]triazin-4-yl]amino]benzamide,

5-[[6-[5-[Difluoro(methylsulfonyl)methyl]-1,3,4-oxadiazol-2-yl]-5-(1-methylethyl)pyrrolo[2,1-f][1,2,4]triazin-4-yl]amino]-2,4-difluoro-N-methoxybenzamide,

5-[[6-[5-(Dimethylamino)-1,3,4-oxadiazol-2-yl]-5-(1-methylethyl)pyrrolo[2,1-f][1,2,4]triazin-4-yl]amino]-2,4-difluoro-N-methoxybenzamide,

4-Fluoro-N-methoxy-3-[[5-(1-methylethyl)-6-(5-methyl-2-oxazolyl)pyrrolo[2,1-f][1,2,4]triazin-4-yl]amino]benzamide,

2,4-Difluoro-N-methoxy-5-[[5-(1-methylethyl)-6-(5-methyl-2-oxazolyl)pyrrolo[2,1-f][1,2,4]triazin-4-yl]amino]benzamide, and

2,4-Difluoro-N-methoxy-5-[[5-(1-methylethyl)-6-(5-methyl-1,2,4-oxadiazol-3-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl]amino]benzamide.

Claim 4 (Currently amended). A pharmaceutical composition comprising ~~at least one~~ one or more of the compounds of Claim 1 and a pharmaceutically acceptable carrier.

Claim 5 (Currently amended). A pharmaceutical composition comprising ~~at least one~~ one or more of the compounds of Claim 1 in combination with pharmaceutically acceptable carrier and an anti-cancer or cytotoxic agent.

Claim 6 (Original). The pharmaceutical composition as recited in Claim 5, wherein said anti-cancer or cytotoxic agent is selected from the group consisting of: linomide, inhibitors of integrin $\alpha v\beta 3$ function, angiostatin, razoxane, tamoxifen, toremifene, raloxifene, droloxifene, iodoxifene, megestrol acetate, anastrozole, letrozole, borazole, exemestane, flutamide, nilutamide, bicalutamide, cyproterone acetate, gosereline acetate, leuprolide, finasteride, herceptin, metalloproteinase inhibitors, inhibitors of urokinase plasminogen activator receptor function, growth factor antibodies, growth factor receptor antibodies, bevacizumab, cetuximab, tyrosine kinase inhibitors, serine/threonine kinase inhibitors, methotrexate, 5-fluorouracil, purine, adenosine analogues, cytosine arabinoside, doxorubicin, daunomycin, epirubicin, idarubicin, mitomycin-C, dactinomycin, mithramycin, cisplatin, carboplatin, nitrogen mustard, melphalan, chlorambucil, busulphan, cyclophosphamide, ifosfamide, nitrosoureas, thiotepa, vincristine, paclitaxel, docetaxel, epothilone analogs, discodermolide analogs, eleutherobin analogs, etoposide, teniposide, amsacrine, topotecan, irinotecan, flavopyridols, proteasome inhibitors including bortezomib and biological response modifiers.

Claim 7 (Currently amended). A method for producing an antiangiogenic effect which comprises administering to a mammalian species in need thereof, an effective antiangiogenic producing amount of ~~at least one~~ one or more of the compounds of Claim 1.

Claim 8 (Currently amended). A method for producing a vascular permeability reducing effect which comprises administering to a mammalian species in need thereof an effective vascular permeability reducing amount of ~~at least one~~ one or more of the compounds of Claim 1.

Claim 9 (Currently amended). A method of inhibiting protein kinase activity of growth factor receptors which comprises administering to a mammalian species in need thereof, an effective protein kinase inhibiting amount of ~~at least one~~ one or more of the compounds of Claim 1.

Claim 10 (Currently amended). A method of inhibiting tyrosine kinase activity of growth factor receptors which comprises administering to a mammalian species in need thereof, an effective tyrosine kinase inhibiting amount of ~~at least one~~ one or more of the compounds of Claim 1.

Claim 11 (Canceled). A method for treating proliferative diseases, comprising administering to a mammalian species in need thereof, a therapeutically effective amount of a composition of Claim 4.

Claim 12 (Canceled). A method for treating cancer, comprising administering to a mammalian species in need thereof, a therapeutically effective amount of a composition of Claim 4.

Claim 13 (Canceled). A method for treating inflammation, comprising administering to a mammalian species in need thereof, a therapeutically effective amount of a composition of Claim 4.

Claim 14 (Canceled). A method for treating autoimmune diseases, comprising administering to a mammalian species in need thereof, a therapeutically effective amount of a composition of Claim 4.

Claim 15 (Canceled). A method for treating proliferative diseases, comprising administering to mammalian species in need thereof, a therapeutically effective amount of a composition of Claim 5.

Claim 16 (Canceled). A method for treating cancer, comprising administering to a mammalian species in need thereof, a therapeutically effective amount of a composition of Claim 5.

Claim 17 (Canceled). A method for treating inflammation, comprising administering to a mammalian species in need thereof, a therapeutically effective amount of a composition of Claim 5.

Claim 18 (Canceled). A method for treating autoimmune diseases, comprising administering to a mammalian species in need thereof, a therapeutically effective amount of a composition of Claim 5.

Claim 19 (Canceled). A method for treating diseases associated with signal transduction pathways operating through growth factor receptors, which comprises administering to a mammalian species in need thereof a therapeutically effective amount of at least one of the compounds of Claim 1.

Claim 20 (Withdrawn). A compound selected from
3-Amino-4-fluoro-*N*-methoxybenzamide,
5-amino-2-methyl-4-fluoro-N-methoxybenzamide,
5-amino-2-methyl-N-methoxycarboxamide, or
5-amino-2,4-difluoro-N-methoxybenzamide.